Cynosure Group’s Boston Scientific BSX Stock Holding History

Cynosure Group’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,486	Closed	-$428K	–	241
2025 Q4	$428K	Buy	+4,486	New	+$440K	0.04%	317

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cynosure Group's BSX Position: Q1 2026 in Review

Cynosure Group sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 4,486 shares — an estimated $428K sold.

Cynosure Group first reported a position in BSX in Q4 2025 and held it in 1 quarter. The position peaked at $428K in Q4 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Cynosure Group reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
Cynosure Group sold 4,486 Boston Scientific shares in Q1 2026, an estimated $428K.
Cynosure Group first reported a position in Boston Scientific in Q4 2025 and held it in 1 quarter.
Cynosure Group's Boston Scientific position peaked at $428K in Q4 2025.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Cynosure Group's 13F filing for Q1 2026, filed 14 May 2026.